Compress Finance Back Office Cycle Time 50-80% in Pharmaceuticals

Audit-grade delivery for a regulated workflow

Compliance officers in pharmaceuticals have seen enough "AI governance frameworks" to recognize when one is theatre. The questions they actually ask are concrete: where does the training or retrieval data come from, who curates it, how do model updates get validated, what happens when the model disagrees with the policy, and how is the operator team trained to override.

We answer each of those concretely in the Build phase. Retrieval data is curated by a named subject-matter expert from your team during Discovery, with a documented refresh cadence and an approval workflow for new sources. Model updates are gated by the evaluation harness: a new candidate model has to beat the incumbent on the labelled test set across multiple metric slices before it is promoted, and the comparison is logged. Policy disagreements surface as escalations, not silent overrides — when the model recommends an action that conflicts with a policy clause, the reviewer queue captures both, the operator decides, and the decision feeds the next iteration of the prompt. Operator training is a deliverable, not an afterthought: we ship the reviewer playbook, the calibration sessions, and the first month of paired-review with your team during the transition out of Build.

The net effect for pharmaceuticals leadership on finance back office is a workflow that holds together under the three audiences that matter — internal audit, compliance, supervisor — without requiring three different versions of the story. The dashboard is the story. The audit log is the evidence. The control map is the framework. All three are live, all three are queryable, and all three are designed for the regulated reality your team operates in.

Disclosure to end-parties is the regulatory dimension most pharmaceuticals workflows handle inconsistently. When an automated system contributed to a decision affecting a customer, what does the customer see, when do they see it, and what is the path to challenge. We draft the disclosure language with your legal team during Build, instrument it in the customer-facing outputs, and log every disclosure event for downstream review. The disclosure layer is not a checkbox — it is the property that lets the workflow defend itself in court if it ever needs to.

Data residency and sovereignty constraints in pharmaceuticals are easier to honor when designed into the architecture than when bolted on later. The retrieval index lives in your cloud region; the model provider is selected to align with your data-residency expectations; the audit log retention follows your jurisdiction's longest plausible review window. These are Discovery-phase decisions, not late-Build pivots, because reversing them costs months.

What actually happens in the first month

If you have ever shipped a non-trivial production system you know the first 30 days are make-or-break. For finance back office in pharmaceuticals, the make-or-break decisions are: what does the labelled test set look like, what is in scope for the integration against CRM, where does the automation boundary sit, and how is the reviewer queue UX going to feel to your operator team. We answer all four in the first two weeks.

Labelled test set: 200 cases minimum by end of week 2, signed off by the engagement sponsor, covering routine, exceptional, ambiguous, and adversarial. Integration scope: documented and bounded by end of week 1, with the data-access plan reviewed by your engineering team. Automation boundary: drawn deliberately in week 2 — full automation lane, drafted-with-review lane, reserved-to-human lane — with confidence thresholds calibrated against the test set. Reviewer UX: prototyped in week 2 with two of your senior operators in the loop, iterated through week 3.

From day 30, the Build sprint shifts to widening the envelope. The decisions made in the first month are the ones that shape the next 12 months of operating the workflow — which is why we resist the temptation to skip ahead to the model layer before the test set and the reviewer UX have been earned.

For pharmaceuticals engagements on finance back office, the first 30 days are not about building features — they are about producing the labelled test set that will govern every subsequent decision. The test set is the most valuable artefact of the engagement, because it is what makes "did this change make the workflow better?" a measurable question instead of an opinion.

We spend week 1 on test-set capture. The operator team picks 200-400 representative cases spanning routine, exceptional, ambiguous, and adversarial. Each case has the expected outcome, the expected reasoning, and the source citations a reviewer would want to see. The test set is reviewed for coverage gaps, signed off by the engagement sponsor, and version-controlled alongside the prompts.

From week 2, every prompt change, retrieval-index update, and threshold calibration is gated by the eval harness running against this test set. Improvements that beat the incumbent across enough metric slices get promoted; changes that look impressive on one slice but regress on another are flagged for review. By the end of Build, the test set has grown to 600-1000 cases, the workflow has been through 15-25 eval cycles, and pharmaceuticals leadership has empirical evidence that the system performs on their data, not on a vendor's demo.

This is the practice most pharmaceuticals AI projects skip because it looks like overhead in the first three weeks. It is the practice that determines whether the workflow survives the third quarter of Run, which is why we treat it as the foundation of Build rather than an afterthought.